Mirum acquires Bile Acid Business from Travere for up to $445M; H1 2023 revenue $53.6M, net income $13.6M

Mirum Pharmaceuticals, Inc.

Acquired Chenodal and Cholbam assets for up to $445M ($210M upfront + up to $235M milestone payments).
PIPE of 8M shares at $26.25 raised ~$202.2M net proceeds to fund acquisition.
Acquired business had net product sales of $53.6M and net income of $13.6M for H1 2023 (unaudited).
Pro forma combined financial statements filed; acquisition closed August 31, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.